CTLA4 and melanoma: Together with our previous results demonstrating the pro- and antitumor nature of nitric oxide, the results reported herein suggest that the measurement of nitric oxide-dependent events and modulation of interferon-dependent pathways may distinguish patients who have prolonged RFS with anti-CTLA-4 antibodies compared to published responses to anti-PD1 based adjuvant checkpoint blockade in melanoma.